AGA Nanotech Wins 2025 EWMA Innovation Award for Battlestar™ Antimicrobial Technology

AGA Nanotech is honoured to have been awarded the 2025 EWMA Innovation Competition Prize at the European Wound Management Association (EWMA) Innovation Forum in Barcelona. The €10,000 award recognises Battlestar™, our proprietary antimicrobial delivery system, as a breakthrough technology capable of transforming the treatment of wound infections.

The award was accepted by CEO Harsha Siani, following a competitive selection process and presentation at the EWMA Innovation Forum, sponsored by Convatec and ProDevLabs.

“This prize recognises solutions with the potential to significantly improve wound care quality and patient outcomes. AGA Nanotech is a well-deserved winner of the 2025 competition,” said Isoherranen Kirsi, President of EWMA.

“Many congratulations to Aga Nanotech and their novel technology. It’s a highly innovative advancement that supports the development of improved solutions for effective wound management,” added Sean Willis, VP R&D, Advanced Wound Care, Convatec.

“Wounds represent a burden on healthcare systems on a level with cancer. Battlestar™ shows clear potential for commercialisation and investment,” said Dr Mitch Sanders, CEO, ProDevLabs.

This award is not only a validation of our approach to tackling antimicrobial resistance and biofilms in wounds, but also a catalyst for future collaborations. Through the EWMA Innovation Alliance, AGA Nanotech will gain ongoing access to a global network of wound care experts, supporting our clinical development, market entry, and strategic partnerships.

We’re grateful to EWMA, Convatec, and ProDevLabs for their continued support in driving innovation that improves patient outcomes.